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Abstract
Background: Cerebrospinal fluid (CSF) biomarkers have gained increasing importance in the diagnostic work-up of
Alzheimer’s disease (AD). The core CSF biomarkers related to AD pathology (Aβ42, t-tau and p-tau) are currently
used in CSF diagnostics, while candidate markers of amyloid metabolism (Aβ38, Aβ40, sAPPα, sAPPβ), synaptic loss
(neurogranin), neuroinflammation (YKL-40), neuronal damage (VILIP-1) and genetic risk (apolipoprotein E) are
undergoing evaluation. Diurnal fluctuation in the concentration of CSF biomarkers has been reported and may
represent a preanalytical confounding factor in the laboratory diagnosis of AD. The aim of the present study was to
investigate the diurnal variability of classical and candidate CSF biomarkers in a cohort of neurosurgical patients
carrying a CSF drainage.
Method: Samples were collected from a cohort of 13 neurosurgical patients from either ventricular (n = 6) or
lumbar (n = 7) CSF drainage at six time points during the day, 1–7 days following the neurosurgical intervention.
Concentrations of the core biomarkers were determined by immunoassays.
Results: Although absolute values largely varied among subjects, none of the biomarkers showed significant
diurnal variation. Site of drainage (lumbar vs. ventricular) did not influence this result. The different immunoassays
used for tau and Aβ markers provided similar results.
Conclusion: Time of day at CSF collection does not ultimately affect the concentration levels of classical and
candidate AD biomarkers. Similar trends were found when using different immunoassays, thus corroborating the
consistency of the data.
Background
Alzheimer’s disease (AD) represents the most common
neurodegenerative disease leading to dementia, and its
prevalence is increasing and becoming a major health
and socioeconomic issue [1]. AD pathology affects the
brain several years before the clinical onset, which is
characterized by a long asymptomatic phase followed by
a prodromal phase with disturbances in episodic mem-
ory, ultimately leading to overt dementia [2]. To enable
early initiation of treatment, especially the day disease-
modifying drugs reach the clinic, early diagnosis is rec-
ommended, which is based on combining clinical symp-
toms and neuropsychological testing with biomarkers
(CSF, imaging) reflecting AD pathology [3]. With respect
to classical CSF biomarkers (Aβ42, total tau, phosphory-
lated tau), large evidence has been collected about their
reliability in supporting the diagnosis of AD [4–6].
In order to introduce the use of biomarkers as part of
the routine diagnostic assessment, standardization of the
procedures is mandatory. Preanalytical factors are re-
ported to be the cause of at least 40–60 % of the total
variability in biomarker measurements [7]. Some key is-
sues were identified for sample collection and analysis,
such as presence of a CSF gradient, blood contamination
of the sample, fasting state of the patient, and other la-
boratory procedures regarding collection and storage of
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the samples (collection tubes, aliquot volume, centrifu-
gation, length and temperature of storage, number of
freeze/thaw cycles).
The major focus of our study is the influence of time
of day at CSF collection which, in a clinical routine sched-
ule, may influence the results obtained. If proved signifi-
cant, the diurnal fluctuations would affect the reliability of
the CSF analysis depending on time at withdrawal. Only
few studies have addressed this issue, giving inconsistent
results: Bateman et al. first observed a significant decreas-
ing trend of Aβ during the 24 h in young individuals [8],
an observation disproved in subsequent studies in older
populations [9–11], the ones more likely to undergo CSF
analysis to assess the risk of memory impairment and AD.
There is also no consensus on the time intervals between
the CSF withdrawals or the volume to be taken.
Regarding analytical factors, different methods and as-
says may also represent another source of variability
[12], but no study has been done on the performance
and reliability of different assays when considering diur-
nal variation as a confounding factor.
Candidate biomarkers
Along with core biomarkers of AD, other proteins are
currently studied as candidate biomarkers, with signifi-
cant results in their role in CSF diagnostics.
Biomarkers of the amyloidogenic pathway are being
taken into account in AD diagnosis, since Aβ42 is pro-
duced from cleavage of amyloid precursor protein (APP).
APP can be cleaved either by α- or β-secretase, releasing
sAPPα or sAPPβ, respectively. After β-secretase cleavage,
the remaining C-terminal fragment is further processed
by γ-secretase which releases Aβ42 along with Aβ38
and Aβ40 fragments, whereas no amyloidogenic frag-
ments are produced after α-secretase cleavage followed
by γ-secretase. Since sAPPα was found decreased and
sAPPβ increased in AD subjects, α- and β- pathway were
considered mutually exclusive [13–16]; however, subse-
quent studies showed positively correlated concentrations
of sAPPα and β [17–19], challenging the hypothesis of an
imbalance between the two isoforms. The several critical
steps of amyloid metabolism can also cause Aβ fluctua-
tions during the day: Dobrowolska et al. found diurnal
fluctuations in sAPPα, sAPPβ, Aβ40, and Aβ42, diminish-
ing with increased age [20].
Regarding genetic risk factors for AD, ApoE is probably
the most important and acknowledged. The three differ-
ent isoforms exert a different effect on AD predisposition:
ApoE4 increases the risk of AD, whereas ApoE2 is a pro-
tective factor, compared to the most common variant
ApoE3. Quantifying ApoE isoforms, especially ApoE4,
could be a useful biological correlate in the study of AD
pathology, but CNS and peripheral ApoE isoform turn-
over rates differ substantially, probably because the ApoE
metabolism pathways are different in the central nervous
system (CNS) and the periphery, as observed in a study by
Wildsmith et al. [21]. Time-dependent fluctuations were
also observed [21, 22].
Also neurogranin (a calmodulin-binding postsynaptic
protein, involved in synaptic signaling, plasticity, long-
term potentiation and memory consolidation) is currently
studied as a potential biomarker. Synaptic loss has been
reported to occur very early in the natural history of AD,
therefore neurogranin can be a valuable biomarker of
early, possible preclinical, stage of the disease [23]. Neuro-
granin concentrations are significantly increased in mild
cognitive impairment (MCI) [24, 25] and can be a predict-
ive factor of conversion to dementia.
Among inflammatory markers we find YKL-40 (also
known as chitinase-3-like protein 1), a protein mainly
expressed by astrocytes. Even if its physiological function
remains unclear [26], it was found to be upregulated in
the AD brain from the preclinical stages of the disease
and may have a role in Aβ deposition [27]. Besides, as a
biomarker, it could also give additional information on
the inflammatory status of the AD brain. However, stud-
ies on its diagnostic and prognostic value still give con-
flicting results [26, 28].
Neuronal damage markers include VILIP-1 (visinin-like
protein 1), a neuronal calcium sensor protein involved in
calcium-mediated neurotoxicity. Not only VILIP-1 is signifi-
cantly increased in AD and could help differentiate AD from
other dementia, but it may also have an influence on tau
metabolism [29, 30]. Moreover, when combined with Aβ42,
it is also a good predictor of cognitive decline [31, 32].
The diurnal variability of the aforementioned biomarkers
has been poorly investigated and no studies are available
on neurogranin, YKL-40 and VILIP-1. Also, most studies
only use one immunoassay type and do not provide a
comparison between different methods.
Aim
In this study we wanted to measure classical (Aβ42, t-tau,
p-tau) and candidate (Aβ38, Aβ40, sAPPα, sAPPβ, apoli-
poprotein E, neurogranin, YKL-40 and VILIP-1) AD bio-
markers in CSF collected at six time points (08:00; 12:00;
16:00; 20:00, 00:00, 08:00) during 24 h to assess these
markers for diurnal variation.
Methods
Participants
We enrolled a total of 13 patients, 8 males (61.5 %) and
5 females (38.5 %), with an age span between 26 and
82 years (Tables 1 and 2). All patients carried a CSF
drainage after neurosurgical intervention for tumors,
traumas or hemorrhages (n = 9) or for monitoring CSF
pressure (n = 4). 7 patients had a lumbar drainage (53.8 %)
and 6 patients had a ventricular drainage (46.2 %), with no
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filter (Codman&Shurtleff, Inc, Raynham, MA, USA). CSF
was collected according to a standard protocol following
international guidelines [33]. The study was approved by
the local Ethical Committee and informed written consent
was signed by all patients enrolled. The work was carried
out according to the Declaration of Helsinki.
CSF collection
According to our protocol, 4 mL CSF were collected at
six time points: 8.00, 12.00, 16.00, 20.00, 00.00 and 8.00.
Haemorrhagic CSF samples were excluded; if the drain-
age was put after a trauma, haemorrhage or tumor surgery
CSF samples collected had to be either clear or slightly
and stably xantochromic (<1000 rbc/μL). CSF was
collected in polypropylene (PP) tubes (Sarsted, code:
62.610.201) and all samples were centrifuged (2000 g ×
10 min, room temperature) no longer than 15 min after
collection, aliquoted in 0.5 ml aliquots (Sarsted, code:
72.730.007) and frozen at −80 °C pending analysis (Table 3).
Assays
Aβ42, t-tau and p-tau were determined with ELISA kit
(Fujirebio) in the Clinical Neurochemistry Laboratory of
the University of Perugia (Perugia, Italy), according to
the manufacturer’s protocol.
Aβ38, Aβ 40, Aβ 42, sAPPα, sAPPβ, neurogranin,
VILIP-1 and YKL-40 were analyzed in the Clinical
Neurochemistry Laboratory of The Sahlgrenska Acad-
emy, University of Gothenburg (Mölndal, Sweden).
MSD V-PLEX Plus kits were used for Aβ38, Aβ40,
Aβ42, sAPPα and sAPPβ, according to the manufac-
turer’s protocol. ELISA kits from R&D and Biovendor
were used for YKL-40 and VILIP-1, respectively, accord-
ing to the manufacturer’s protocol.
An in-house developed assay was used for neurogra-
nin, according to previous reports [24]. Briefly, in-house
antibody Ng7 diluted in PBS was used as coating, a
rabbit anti-neurogranin antibody (ab23570, cat. no. 07-
425, Upstate, Lake Placid, NY, USA) as primary and a
goat anti-rabbit sulfo-tag antibody (MSD) for detection.
Full-length Ng 1–78 protein (ADx) was used as calibra-
tor for the standard curve.
Aβ38, Aβ40, Aβ42, t-tau, and ApoE were also measured
with Euroimmun kits at ADx NeuroSciences (Gent,
Belgium).
Table 1 Age, clinical features of the patients and type of drainage
Patient Age Case of drainage placement Type of drainage
1 48 Third ventricle tumor ventricular
2 73 Left middle cerebral artery infarct ventricular
3 81 Subarachnoid hemorrhage ventricular
4 72 Intracranial hemorrhage lumbar
5 67 Cerebellar hemorrhage ventricular
6 69 Cerebellopontine angle tumor lumbar
7 74 Normal pressure hydrocephalus lumbar
8 36 Head trauma ventricular
9 63 Intracranial hemorrhage ventricular
10 58 Tetraventricular hydrocephalus lumbar
11 77 Normal pressure hydrocephalus lumbar
12 82 Normal pressure hydrocephalus lumbar
13 26 Pseudotumor cerebri lumbar
Table 2 Demographics (mean ± standard deviation or count
with percentages)
Age 63.5 ± 17.3
Sex Male: 8 (61.5 %)
Female: 5 (38.5 %)
Type of drainage Lumbar: 7 (53.8 %)
Ventricular: 6 (46.2 %)
Cause of drainage
placement
Cerebellar hemorrhage: 1 (7.7 %)
Cerebellopontine angle tumor: 1 (7.7 %)
Head trauma: 1 (7.7 %)
Intracranial hemorrhage: 2 (15.4 %)
Left middle cerebral artery infarct: 1 (7.7 %)
Normal pressure hydrocephalus: 3 (23.1 %)
Pseudotumor cerebri: 1 (7.7 %)
Subarachnoid hemorrhage: 1 (7.7 %)
Tetraventricular hydrocephalus: 1 (7.7 %)
Third ventricle tumor: 1 (7.7 %)
Table 3 CSF collection procedures and sample processing
Subjects: 13 neurosurgical patients carrying a CSF drainage
8 M, 5 F; 26 to 82 y
Admitted for tumor, trauma, hemorrhage (n = 9),
CSF pressure monitoring (n = 4)
CSF collection: From lumbar (n = 7) or ventricular (n = 6) drainage
Volume: 4 mL in PP Sarsted tubes, code: 62.610.201
Time of day: 8.00, 12.00, 16.00, 20.00, 00.00, 8.00
CSF processing: Centrifugation within 15 min, 2000 g × 10 min at RT
0.5 mL aliquots in PP Sarsted tubes, code: 72.730.007
CSF storage: −80 °C freezer, with controlled temperature, alarm
and CO2 backup system
Thawing: RT with gentle shaking
Biomarker
measurement:
Immunoassay (Fujirebio): Aβ1-42, t-tau, p-tau181
Immunoassay (Biovendor): VILIP-1
Immunoassay (R&D): YKL-40
Immunoassay (Euroimmun): Aβ1-38, Aβ1-40, Aβ1-42,
t-tau, ApoE
Immunoassay (in-house): neurogranin
Immunoassay (MSD): Aβx-38, Aβx-40, Aβx-42, sAPPα, sAPPβ
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Together with the quality control (QC) samples in-
cluded in the kits, CSF pools were run in each plate as fur-
ther internal controls to check for variability, as previously
described [34]. Performance data (inter- and intra assay
variability, recovery and linearity) can be found at the fol-
lowing references [34, 35].
Statistical analysis
Statistical analysis was performed using R v 13.1 and
Graph Pad v 6.0. Continuous variables were reported as
means, standard deviations and ranges. Categorical vari-
ables were shown as counts and percentages. Continuous
variables were tested for normality with Shapiro–Wilk
test. Differences in biomarkers levels across time points
were tested by means of non-parametric version of re-
peated measurement ANOVA based on aligned ranks,
due to the non-normality of the majority of parameters.
Spearman’s r correlation coefficients of biomarkers con-
centrations were calculated pooling all the time points.
Drainage type was tested as potential confounder in the
fluctuations of biomarkers across time points. Bland-
Altman plots were drawn to investigate the agreement of
different assays for some of the investigated biomarkers
(Aβ38, Aβ40, Aβ42, t-tau). P < 0.05 was chosen as the
minimum level of statistical significance.
Results
Circadian trends in the individual classical and candidate
biomarkers
Aβ38, Aβ40, Aβ42 and t-tau measured with different
methods, i.e. immunoassay by Euroimmun, Fujirebio, and
MSD, showed significant positive correlations (Fig. 1). Re-
sults from Euroimmun vs. MSD highly correlated for both
Aβ38 (r = 0.89, p < 0.01, 95 % confidence interval (CI) =
0.82 to 0.94) and Aβ40 (r = 0.87, p < 0.01, 95 % CI = 0.74
to 0.9). Similar results were found for Aβ42 when compar-
ing Euroimmun vs. MSD (r = 0.92, p < 0.01, 95 % CI = 0.82
to 0.93), Euroimmun vs. Fujirebio (r = 0.81, p < 0.01, 95 %
CI = 0.74 to 0.9) and MSD vs. Fujirebio (r = 0.86, p < 0.01,
95 % CI = 0.74 to 0.89) (Fig. 1).
There was also a positive correlation for tau when
measured with Fujirebio and Euroimmun (r = 0.67,
p < 0.01, 95 % CI = 0.48 to 0.8). Bland-Altman ana-
lysis was used to assess the agreement among the
Fig. 1 Correlation of the levels of biomarkers measured with different assays (Euroimmun, MSD, Fujirebio)
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different assays for measuring absolute concentrations of
the biomarkers (Additional file 1).
Notably, MSD assays overall showed differences either
when compared to Euroimmun or Fujirebio assays. This
was especially evident for Aβ42 and Aβ40 which showed
the largest variation in the difference between the two as-
says across the whole range of concentrations (Additional
file 1).
As expected from the different admittance diagnosis,
sex and age of the population (Tables 1 and 2), absolute
concentrations of the biomarkers were very different
among patients (Table 4). For what concerns classical
biomarkers, in the whole population Aβ42 ranged from
71 to 1253.4 pg/mL, t-tau from 29 to 1501 pg/mL and
p-tau from 15 to 113 pg/mL.
Possibly due to their common metabolism pathway,
amyloid metabolism markers (Aβ38, Aβ40, Aβ42, sAPPα,
sAPPβ) showed similar trends over time in the whole popu-
lation (Figs. 2 and 3). However, none of them had signifi-
cant variation across time points (p > 0.05). sAPPα, sAPPβ
and β-amyloid fragments correlated positively with each
other, with r values ranging from to 0.54 to 0.97 (p > 0.01)
(Additional file 2). When measured with Euroimmun kits,
Aβ42/β40 and Aβ38/40 ratio showed no significant oscil-
lations (p > 0.05). No significant intraindividual fluctua-
tions over time were found for any of the Aβ markers
when measured with the different assays (for Aβ42, see
Additional file 3).
Neither T-tau nor P-tau did show a significant diurnal
variation (Figs. 2 and 3). No significant oscillations were
observed for Neurogranin, ApoE, YKL-40 and VILIP-1
(p > 0.05) (Fig. 2). Single patients showed some
variations for specific proteins but globally no significant
fluctuations over time were observed.
Site of drainage
When site of drainage was considered as a covariate in
non-parametric repeated measurements ANOVA based
on aligned ranks, variability in some of the proteins (Aβ38,
Aβ40, YKL40, t-tau) was found to be significantly explained
by the site of drainage (p < 0.05), with generally higher con-
centration in CSF from ventricular catheter. Anyway, sub-
group analyses restricted to lumbar or ventricular catheter
showed no significant changes across the time points ana-
lysed (p > 0.05) (Fig. 4). Similar results were obtained when
the analysis was repeated considering only patients with
normal pressure hydrocephalus (n = 3, p > 0.05).
Discussion
In our study we assessed the possible circadian oscilla-
tion of classical (Aβ42, t-tau, p-tau) and candidate
(Aβ38, Aβ40, sAPPα, sAPPβ, apolipoprotein E, neuro-
granin, YKL-40, VILIP-1) CSF AD biomarkers. Previous
studies addressed the issue of diurnal fluctuations of Aβ
and tau in CSF (for review see [36]), however, a signifi-
cant circadian oscillation of Aβ was detected only in the
study by Bateman and colleagues [8]. Moreover, the
study included subjects significantly younger than the
ones who usually undergo lumbar puncture as a diag-
nostic procedure (23 to 78 years old).
Subsequent studies did not observe the same trend
[9–11]. Bjerke et al. led a study in healthy subjects
undergoing knee surgery and observed a slight decrease
in Aβ42 levels, which tended to return to baseline after
24 h [10]. Slats et al. compared the trends of Aβ in
healthy and mild AD subjects, noticing no significant di-
urnal variation and also a less pronounced circadian pat-
tern compared with the one in younger subjects (59 to
85 years old) [11]. Only Moghekar et al. examined also
tau along with Aβ, in a cohort of normal pressure hydro-
cephalus subjects, but no diurnal fluctuation of the bio-
markers was reported [9].
Our study is in line with the majority of the results
from previous ones, but we also investigated the possible
oscillations of the latest candidate AD biomarkers
(neurogranin, YKL-40, VILIP-1). We collected a smaller
volume of CSF (4 mL) than in previous studies (from 6
to 40 mL) to avoid possible fluctuations due to tapping
large volumes of CSF, and we compared results from
ventricular CSF and lumbar CSF to detect a possible gra-
dient effect.
Although CSF protein concentrations were signifi-
cantly different from one patient to another, none of the
biomarkers showed a significant diurnal variation. The
ranges of the biomarkers were very different from the
ones available from the literature on optimal cut-offs for
Table 4 Concentration range of the biomarkers (with median)
Biomarker Median (IQR) Min - Max
Aβ38 MSD (pg/mL) 990.9 (440.1–1396.0) 33.3–2573.0
Aβ40 MSD (pg/mL) 2514.9 (1154.8–3356.5) 79.3–5880.5
Aβ42 MSD (pg/mL) 182.1 (54.1–266.6) 5.5–921.2
Aβ38 Euroimmun (pg/mL) 1247.7 (1120.9–1462.0) 277.5–2492.5
Aβ40 Euroimmun (pg/mL) 4669.0 (3605.0–5305.0) 1487.0–9382.2
Aβ42 Euroimmun (pg/mL) 337.9 (191.9–521.8) 70.6–1253.4
t-tau Euroimmun (pg/mL) 464.7 (223.0–917.6) 29.3–1501.0
Aβ42 Fujirebio (pg/mL) 568.0 (294.5–786.0) 91.0–1507.0
t-tau Fujirebio (pg/mL) 319.0 (180.2–742.2) 72.0–1832.0
p-tau (pg/mL) 43.0 (30.3–52.8) 15.0–113.0
sAPPα (ng/mL) 60.4 (32.5–178.8) 4.3–429.6
sAPPβ (ng/mL) 66.4 (25.5–175.0) 1.4–313.6
YKL-40 (ng/mL) 264.6 (151.9–348.4) 65.4–1020.0
VILIP-1 (pg/mL) 113.5 (99.0–135.0) 72.0–781.0
Neurogranin (pg/mL) 354.5 (275.9–435.4) 46.3–1291.1
ApoE (ng/mL) 24.5 (18.8–44.4) 3.4–104.2
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AD biomarkers [37]. This is mostly due to the hetero-
geneity of the population, different for sex, age and diag-
nosis at admission (Tables 1 and 2). The subjects did all
undergo an invasive procedure for catheter insertion,
which might have affected the levels of the biomarkers
in CSF. Moreover, 9 out of 13 subjects underwent brain
surgery for tumours, haemorrhage or head trauma prior
to drainage placement, which is most likely the reason
for the generally upregulated values of inflammatory and
brain injury markers (tau, YKL-40) in the population.
Not to be excluded is also the presence of a possible
underlying AD pathology in the older subjects. It is re-
markable, however, that even if set on different ranges
between subjects, the overall levels of the individual bio-
markers are very stable over time and do not seem to be
affected by external factors.
Site of drainage significantly influenced the variability
of some of the biomarkers (Aβ38, Aβ40, YKL40, t-tau),
as previously described [38], with generally higher con-
centration in CSF from ventricular catheter, most likely
due to the increased concentrations of injury markers in
the site of the surgical intervention or brain damage in
patients carrying a ventricular drainage.
Some of the analytes tested in this work were mea-
sured with different immunoassays (Fujirebio, MSD, and
Euroimmun). Absolute concentrations of the biomarkers
using different immunoassays varied widely, possibly due
to the different sources for the calibrators used by the
manufacturers, as well as to the different antibodies used
for coating and detection. No previous studies on circa-
dian rhythms of CSF biomarkers have been performed
comparing these three different techniques, which
nevertheless showed good inter-assay correlations, prov-
ing the reliability of the methods in use and supporting
the lack of circadian oscillations independently from the
technique.
The main limitation of this study was the population,
mostly admitted to hospital for traumatic intervention,
limited in number and very different for age and disease.
However, patients with normal pressure hydrocephalus,
which were admitted to hospital only for diagnostic pur-
poses and represented a more selected population, did not
show significant diurnal variability as well. Obviously, to
find ventricular CSF samples suitable for biomarker ana-
lysis is not easily manageable, due to the severe underlying
conditions that lead to the insertion of a ventricular
Fig. 2 Concentration levels of the biomarkers across time points (horizontal lines representing the median, box representing the 25th and 75th
percentiles, whiskers representing the 5th and 95th percentiles, and outliers represented by dots)
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Fig. 4 Concentration levels of several biomarkers with different type of drainage (lumbar or ventricular) across time points (horizontal lines representing
the median, box representing the 25th and 75th percentiles, whiskers representing the 5th and 95th percentiles). Pictures not showed for
non-significant comparisons
Fig. 3 Concentration levels of several biomarkers measured with different assays (Euroimmun, MSD, Fujirebio) across time points (horizontal lines
representing the median, box representing the 25th and 75th percentiles, whiskers representing the 5th and 95th percentiles)
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catheter. Same is for lumbar CSF: not being possible to
perform multiple lumbar punctures during the day, re-
peated measurements at different time points can only be
done after insertion of a drainage, which is seen as a dan-
gerous procedure by most of the population, making it
problematic to enrol healthy controls and AD subjects in
larger studies. Further efforts are needed to raise public
awareness about the minor risks of this kind of procedure,
especially in view of an early diagnosis of AD pathology.
Conclusions
In view of standardizing CSF collection and analysis pro-
cedures, the absence of an influence on classical and
candidate CSF biomarker of time at sampling make
them a valuable asset in the diagnostic work-up of AD.
Independence from time of day is also crucial for clinical
practitioners: being bound to fixed hospital schedules,
the possibility to perform the lumbar puncture at any
time of the day is of great importance.
An increasing number of tools are already being devel-
oped for the measurement of these analytes in CSF and
preliminary results show robustness and significant over-
lap between different methods, proving their reliability
and reproducibility for biomarker analysis. However, lar-
ger and selected populations are needed to increase the
power of these findings.
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